hexamethonium has been researched along with Nerve Degeneration in 1 studies
Hexamethonium: A nicotinic cholinergic antagonist often referred to as the prototypical ganglionic blocker. It is poorly absorbed from the gastrointestinal tract and does not cross the blood-brain barrier. It has been used for a variety of therapeutic purposes including hypertension but, like the other ganglionic blockers, it has been replaced by more specific drugs for most purposes, although it is widely used a research tool.
Nerve Degeneration: Loss of functional activity and trophic degeneration of nerve axons and their terminal arborizations following the destruction of their cells of origin or interruption of their continuity with these cells. The pathology is characteristic of neurodegenerative diseases. Often the process of nerve degeneration is studied in research on neuroanatomical localization and correlation of the neurophysiology of neural pathways.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Marin, P | 1 |
| Maus, M | 1 |
| Desagher, S | 1 |
| Glowinski, J | 1 |
| Prémont, J | 1 |
1 other study available for hexamethonium and Nerve Degeneration
| Article | Year |
|---|---|
Nicotine protects cultured striatal neurones against N-methyl-D-aspartate receptor-mediated neurotoxicity.
Topics: Acetylcholine; Animals; Carbachol; Cells, Cultured; Dimethylphenylpiperazinium Iodide; Hexamethonium | 1994 |